Bioxel Pharma Inc.

Bioxel Pharma Inc.

November 02, 2006 08:00 ET

Bioxel Expands Paclitaxel Registrations in Europe and Makes its Mark in Russia

SAINTE-FOY, QUEBEC--(CCNMatthews - Nov. 2, 2006) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, is pleased to announce that it has filed its paclitaxel European Drug Master File (EDMF) in an additional four EU countries and also in Russia, bringing to fifteen the total number of countries in which the Corporation markets or plans to market its paclitaxel.

DMF registrations in these regulated markets are a prerequisite to selling paclitaxel API. So with the addition of each country, Bioxel is securing well-diversified future revenue streams. Bioxel has already exceeded its DMF registrations objective for 2006, and intends to intensify its paclitaxel supplies throughout Europe by 2007.

"We see in this new registration round not only the strengthening of our commercial presence in Europe and the broadening of our customer base, but also the increasing role of Bioxel on the worldwide taxane APIs market," said Pascal Delmas, President and CEO of Bioxel Pharma. "Building on a limited European presence at the beginning of 2006, our geographical reach now covers the largest EU generic markets and emerging Eastern EU countries, including Germany, Italy, Portugal, Greece, Poland, and the Czech Republic to name a few. We are also proud to get a foothold in Russia, a promising and rapidly-growing generic market."

Bioxel's paclitaxel EDMF is submitted to national health agencies at the request of its clients, which are leading European generic companies. These companies have selected Bioxel's paclitaxel on rigorous buying criteria covering competitiveness and reliability of supply, as well as product quality and compliance.


Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

Contact Information